New drug Molnupiravir raises hope for mild Covid-19 cases

Going by data available so far, doctors say this could be useful in treating Covid patients in early stages, as the company reported a 50% drop in hospitalisation and death.

Published: 05th October 2021 02:59 AM  |   Last Updated: 05th October 2021 09:01 AM   |  A+A-

Representational image of Coronavirus.

Representational Image. (File Photo)

By Express News Service

BENGALURU: The experimental Covid-19 drug Molnupiravir could be promising in treating mild to moderate corona patients, going by the announcement made on October 2 by the company, Merck and Ridgeback Biotherapeutic, after completing Phase 3 trials.

Going by data available so far, doctors say this could be useful in treating Covid patients in early stages, as the company reported a 50% drop in hospitalisation and death.

“While we have medicines for moderate to severe patients, we are still struggling for mild patients. This drug could be a gamechanger. It can be taken orally in the out-patient department,” said Dr Chinnadurai R, lead consultant, Department of Critical Care, Aster RV Hospital.

The data was drawn from 775 patients and reported 7.3% of patients who received the drug were either hospitalised or had died by day 29, compared to 14.1% of placebo patients.

“Molnupiravir induces ‘lethal mutagenesis’, thereby reducing viral replication; Study is yet to be peer reviewed and published. We have to see clinical benefit on the ground and also await regulatory approval,” said Dr Anoop Amarnath, head, Scientific Board and chairman, Geriatric Medicine, Manipal Hospitals.

In India, five companies are conducting trials for this drug — Cipla, Dr Reddy’s, Emcure, Sun Pharma and Torrent.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp